The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Avastin) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, July 04, 2010

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Avastin)



Results 

Thirty-eight patients were included. All patients were heavily pre-treated with a median of five prior regimens. ..... The VEGF serum level decreased during treatment in all patients. A low pre-treatment VEGF level was predictive to response. 

Conclusions

Single agent bevacizumab has activity in ovarian cancer patients. Pre-treatment serum VEGF seems to have predictive value.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.